| Identification | Back Directory | [Name]
CT52923 | [CAS]
205256-55-9 | [Synonyms]
CT52923
1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-(6,7-dimethoxy-4-quinazolinyl)- | [Molecular Formula]
C23H25N5O4S | [MOL File]
205256-55-9.mol | [Molecular Weight]
467.54 |
| Chemical Properties | Back Directory | [Melting point ]
113-114 °C(Solv: ethyl acetate (141-78-6)) | [Boiling point ]
652.5±65.0 °C(Predicted) | [density ]
1.370±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.98±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer[1]. | [in vivo]
CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat[1]. | Animal Model: | Rat carotid artery balloon angioplasty model[1].
| | Dosage: | 5, 15, 30, and 50 mg/kg | | Administration: | Oral gavage; twice daily | | Result: | Inhibited PDGF-mediated response to vascular injury. |
| [References]
[1] J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8. PMID:11504817 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|